Pfizer (NYSE:PFE) and its partner BioNTech (NSDQ:BNTX) announced that they will submit a request today with FDA for an EUA of their mRNA vaccine candidate, BNT162b2, against SARS-CoV-2.
If all goes as planned, the companies predict that high-risk populations in the U.S. could start receiving the vaccine by mid- to late-December. Vaccine distribution could start within hours of FDA authorization. The companies expect to produce up to 50 million doses worldwide in 2020, with 1.3 billion doses produced by the end of 2021.
Get the full story on our sister site Drug Discovery & Development.